Search results for "Plasma glucose"

showing 7 items of 7 documents

Red cell sorbitol concentration in relation to short- and medium-term variation of plasma glucose.

1989

To evaluate the time course of changes in red cell sorbitol (RCS) concentration in relation to variations of plasma glucose levels, RCS was determined in 7 normal subjects during i.v. glucose infusion (IVGTT); in 6 hyperglycemic insulin-dependent diabetic subjects while glycemia was normalized with Biostator GC 115 and in 4 diabetic patients in previously poor metabolic control, in whom normal glycemia was obtained in 8–10 days by intensive insulin therapy. During IVGTT, plasma glucose levels increased with significant differences from baseline at 5, 10, 16, 25, 60, 100 and 160 min and returned to basal levels after 3h; RCS concentration showed small and insignificant increases. During i.v.…

Activity CyclesBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentmacromolecular substancesMedium termchemistry.chemical_compoundEndocrinologyReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansSorbitolPlasma glucoseRed Cellbusiness.industryInsulinGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseCircadian RhythmEndocrinologyDiabetes Mellitus Type 1GlucoseBasal (medicine)chemistryMetabolic control analysisHyperglycemiaSorbitolbusinessActa diabetologica latina
researchProduct

Resting Energy expenditure in type 2 diabetic patients and the effect of insulin bolus

2014

Aims: Resting energy expenditure (REE) plays a critical role in the regulation of body weight, with important implications in type 2 diabetes (T2D). However, the relationships between REE and T2D have not been extensively evaluated. We compared REE in persons with diabetes and in persons without diabetes. We also investigated the acute effect of insulin on REE and venous lactate, the latter an indirect measure of neoglucogenetic activity. Methods: REE was measured using indirect calorimetry in 14 newly diagnosed, untreated T2D adults and in 14 non-diabetic age-, gender- and body mass index-matched persons. The REE and lactate venous concentrations were also measured in a subgroup of 5 T2D p…

AdultBlood GlucoseMalemedicine.medical_specialtyRestEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesBody weightBody Mass IndexSettore MED/13 - EndocrinologiaEndocrinologyBolus (medicine)Internal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinResting energy expenditureSettore MED/49 - Scienze Tecniche Dietetiche ApplicateAgedbusiness.industryInsulinBody WeightCalorimetry IndirectGeneral MedicinePlasma glucose concentrationMiddle Agedmedicine.diseasediabetes insulin lactate neoglucogenesis resting energy expenditure indirect calorimetryEndocrinologyDiabetes Mellitus Type 2GluconeogenesisFemaleEnergy IntakeEnergy MetabolismbusinessFollow-Up Studies
researchProduct

Classical cardiovascular risk factors according to fasting plasma glucose levels

2007

To compare the prevalence of classical cardiovascular risk factors (CVRF) and metabolic syndrome (MetS) in our population according to fasting plasma glucose levels (FPG).We have studied 344 subjects between 20-70 years of age, recruited in a Primary Care Clinic. Subjects were divided into four groups according to their fasting plasma glucose (FPG) values: normal plasma glucose (NG) when FPG5.6 mmol/L; FPG between 5.6 and 6.0 mmol/L (FPG1); FPG between 6.1-6.9 mmol/L (FPG2); and diabetes (DM) FPGor = 7 mmol/L or previous diagnosis of diabetes. Cardiovascular risk factors (hypertension, TC/HDL-C index and Apo B values), presence of the MetS and indirect measure of insulin resistance (HOMA) w…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesPopulationCardiovascular risk factorsComorbiditySeverity of Illness IndexRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumanseducationPractical implicationsAgedMetabolic Syndromeeducation.field_of_studyPlasma glucosebusiness.industrynutritional and metabolic diseasesType 2 Diabetes MellitusFastingMiddle AgedImpaired fasting glucosemedicine.diseasePrimary care clinicCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesSpainFemaleMetabolic syndromebusinessEuropean Journal of Internal Medicine
researchProduct

Glucose and Erythrocyte ATP: Distinctive Effects of Dipyridamole and of Ticlopidine

1987

This experiment suggests the following points: 1. Erythrocytes in control patients and in atherosclerosis patients seem to have a variable grade of affinity for adenosine and for plasma glucose. This variable grade seems to fix the level of the adenosine triphosphate (ATP) reserves and induces the erythrocytes' deformability. 2. The drop in the level of ATP reserves that induces the poor deformability of the erythrocytes in atherosclerosis patients would appear to be caused by two consecutive shortages: first a shortage that seems to be related to a deficiency of erythrocyte adenosine as the ATP shortage disappears with dipyridamole treatment and then a shortage induced by the lack of eryt…

Blood Glucosemedicine.medical_specialtyAdenosineErythrocytesTiclopidineArteriosclerosismedicine.medical_treatmentEconomic shortage030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundAdenosine Triphosphate0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineTiclopidineChemotherapyPlasma glucosebusiness.industryDipyridamoleAdenosineDipyridamoleRed blood cellEndocrinologymedicine.anatomical_structurechemistryDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessAdenosine triphosphatemedicine.drugAngiology
researchProduct

A Multiple Local Models Approach to Accuracy Improvement in Continuous Glucose Monitoring

2011

Continuous glucose monitoring (CGM) devices estimate plasma glucose (PG) from measurements in compartments alternative to blood. The accuracy of currently available CGM is yet unsatisfactory and may depend on the implemented calibration algorithms, which do not compensate adequately for the differences of glucose dynamics between the compartments. Here we propose and validate an innovative calibration algorithm for the improvement of CGM performance.CGM data from GlucoDay(®) (A. Menarini, Florence, Italy) and paired reference PG have been obtained from eight subjects without diabetes during eu-, hypo-, and hyperglycemic hyperinsulinemic clamps. A calibration algorithm based on a dynamic glo…

Blood Glucosemedicine.medical_specialtyCalibration (statistics)Endocrinology Diabetes and MetabolismMonitoring Ambulatory030209 endocrinology & metabolismBiosensing TechniquesAccuracy improvementSensitivity and Specificity01 natural sciencesGlobal model03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineBlood Glucose Self-MonitoringDiabetes MellitusmedicineHumansGlucose dynamicsPlasma glucoseContinuous glucose monitoringbusiness.industryBlood Glucose Self-Monitoring010401 analytical chemistryReproducibility of ResultsPattern recognition0104 chemical sciencesMedical Laboratory TechnologyEndocrinologyCalibration algorithmArtificial intelligencebusinessAlgorithmsDiabetes Technology & Therapeutics
researchProduct

Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

2019

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta-analysis of the available randomized, double-blind, placebo-controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combina…

Blood Glucosemedicine.medical_specialtysilymarinReviewsBlood lipidsberberine; cholesterol; fasting plasma glucose; meta-analysis; nutraceutical; silymarin; Berberine; Blood Glucose; Double-Blind Method; Fasting; Humans; Lipids; Randomized Controlled Trials as Topic; SilymarinReviewPlaceboGastroenterologymeta-analysiDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDouble-Blind MethodInternal medicineberberineMedicineHumansfasting plasma glucoseRandomized Controlled Trials as TopicPharmacology0303 health sciencesbusiness.industryCholesterolData synthesis030302 biochemistry & molecular biologycholesterolFastingLipidsClinical trialmeta-analysischemistrymeta‐analysis030220 oncology & carcinogenesisMetabolic effectsMeta-analysisnutraceuticalCardiology and Cardiovascular Medicinebusiness
researchProduct

P4570Prognostic interest of HbA1c and plasma glucose assessment on one-year mortality in non-diabetic patients after acute myocardial infarction

2019

Abstract Background The usefulness of the combined assessment of HbA1c and plasma glucose (PG) in acute myocardial infarction (AMI) in nondiabetic patients remains unclear. Purpose In a large observational study, we aimed to identify the prognostic values of these biomarkers regarding one-year all-cause mortality in nondiabetic patients after AMI. Methods From the “obseRvatoire des Infarctus de Côte d'Or” (RICO) survey database, we included all consecutive nondiabetic patients with AMI (n=6617) from May 2001 to December 2016. Exclusion criteria were: admission known or unknown diabetes, in-hospital death. The primary endpoint was all-cause one-year mortality. The secondary endpoints were: M…

One year mortalityPlasma glucosemedicine.medical_specialtybusiness.industryInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular Medicinemedicine.diseasebusinessNon diabeticEuropean Heart Journal
researchProduct